Entity

Time filter

Source Type

Toronto, Canada

Sridhar S.S.,University of Toronto | Canil C.M.,Ottawa Regional Cancer Center | Chi K.N.,BC Cancer Agency | Hotte S.J.,Juravinski Cancer Center | And 8 more authors.
Cancer Chemotherapy and Pharmacology | Year: 2011

Purpose: GTI-2040 is a novel antisense oligonucleotide to the R2 subunit of ribonucleotide reductase. This phase II trial was conducted to determine the efficacy and tolerability of GTI-2040 when combined with docetaxel and prednisone for the treatment of patients with castration-resistant prostate cancer (CRPC). Methods: Chemo-naïve CRPC patients with adequate performance status and organ function were treated with docetaxel 75 mg/m2 IV on day 1 plus GTI-2040 5 mg/kg/day by continuous intravenous infusion day 1-14 on a 21 day cycle, with prednisone 5 mg orally twice daily. The primary endpoint was PSA response rate. Pharmacokinetic studies of GTI-2040 and pharmacodynamic studies on peripheral blood mononuclear cells (PBMC) were also performed. Results: Twenty-two patients in total (19 from this study and 3 from a prior phase I/II study at this institution) were treated at the recommended phase II dose. A confirmed PSA response was seen in 9/22 patients (41%). Of 16 patients with measurable disease, there was 1 partial response (PR) and 12 stable disease (SD) lasting 3.6 months (median), as best response. The most common toxicities were anemia, fatigue, lymphopenia, leucopenia and neutropenia. Grade 3+ toxicities included neutropenia, lymphopenia, leucopenia, fatigue, febrile neutropenia and hypophosphatemia. Conclusions: The PSA response rate of GTI-2040 in combination with docetaxel and prednisone just met the minimum phase II criteria for further enrollment. However, after evaluation of all the clinical data, further study of this dose and schedule of GTI-2040 in CRPC was not recommended. © 2010 Springer-Verlag. Source


Trademark
Lorus Therapeutics Inc. | Date: 2009-09-15

Pharmaceutical preparations for the treatment of cancer.


The present invention provides antisense oligonucleotides directed to a mammalian ribonucleotide reductase R2 gene and combinations of the antisense oligonucleotides with one or more chemotherapeutic agents for use in the treatment of cancer.


Small interfering RNA (siRNA) molecules that target a mammalian ribonucleotide reductase gene, and which are capable of inhibiting the expression of their target gene are provided. The siRNA molecules of the invention are capable of attenuating neoplastic cell growth and/or proliferation in vitro and in vivo and, therefore, can be used to attenuate the growth and/or metastasis of various types of mammalian cancers.


Trademark
Aptose Biosciences Inc. and Lorus Therapeutics Inc. | Date: 2014-10-22

pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in the fields of oncology, genetics and hematology; diagnostic preparations for use in the fields of oncology, genetics and hematology. scientific and medical research services. Providing information to patients in the fields of cancer prevention, screening, diagnosis and treatment.

Discover hidden collaborations